Dow Jones

42,175.11

0.00%

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

BHVN

Biohaven (BHVN)

Biohaven Ltd

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:BHVN

1 2 3 4 5 6 7 8 9 10 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
24/09/2024	05:15	IH Market News	Visa Faces Monopoly Lawsuit; Meta Introduces Celebrity Voices for Chatbot; Stellantis on the Hunt for New CEO	NYSE:BHVN	Biohaven Ltd
23/09/2024	08:11	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:BHVN	Biohaven Ltd
23/09/2024	06:30	PR Newswire (US)	Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)	NYSE:BHVN	Biohaven Ltd
20/09/2024	18:09	PR Newswire (US)	Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia	NYSE:BHVN	Biohaven Ltd
16/08/2024	15:31	Edgar (US Regulatory)	Form 424B7 - Prospectus [Rule 424(b)(7)]	NYSE:BHVN	Biohaven Ltd
16/08/2024	15:21	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NYSE:BHVN	Biohaven Ltd
09/08/2024	15:06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:BHVN	Biohaven Ltd
08/08/2024	15:05	PR Newswire (US)	Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments	NYSE:BHVN	Biohaven Ltd
29/05/2024	06:30	PR Newswire (US)	Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day	NYSE:BHVN	Biohaven Ltd
29/05/2024	06:15	PR Newswire (US)	Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors	NYSE:BHVN	Biohaven Ltd
09/05/2024	15:16	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NYSE:BHVN	Biohaven Ltd
09/05/2024	15:05	PR Newswire (US)	Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments	NYSE:BHVN	Biohaven Ltd
22/04/2024	15:05	PR Newswire (US)	Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares	NYSE:BHVN	Biohaven Ltd
17/04/2024	15:05	PR Newswire (US)	Biohaven Announces Proposed Public Offering of Common Shares	NYSE:BHVN	Biohaven Ltd
13/04/2024	08:00	PR Newswire (US)	Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates	NYSE:BHVN	Biohaven Ltd
29/02/2024	15:05	PR Newswire (US)	Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments	NYSE:BHVN	Biohaven Ltd
08/01/2024	06:30	PR Newswire (US)	Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncolo	NYSE:BHVN	Biohaven Ltd
02/01/2024	06:00	PR Newswire (US)	Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NYSE:BHVN	Biohaven Ltd
01/12/2023	15:30	PR Newswire (US)	Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting	NYSE:BHVN	Biohaven Ltd
14/11/2023	15:05	PR Newswire (US)	Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments	NYSE:BHVN	Biohaven Ltd
16/10/2023	06:00	PR Newswire (US)	Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®	NYSE:BHVN	Biohaven Ltd
02/10/2023	22:56	PR Newswire (US)	Biohaven Announces Pricing of $225 Million Public Offering of Common Shares	NYSE:BHVN	Biohaven Ltd
02/10/2023	15:36	PR Newswire (US)	BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES	NYSE:BHVN	Biohaven Ltd
02/10/2023	15:01	Edgar (US Regulatory)	Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers	NYSE:BHVN	Biohaven Ltd
14/09/2023	06:00	PR Newswire (US)	Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy	NYSE:BHVN	Biohaven Ltd
05/09/2023	06:00	PR Newswire (US)	Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies	NYSE:BHVN	Biohaven Ltd
31/07/2023	08:31	PR Newswire (US)	Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy	NYSE:BHVN	Biohaven Ltd
31/07/2023	05:59	PR Newswire (US)	Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments	NYSE:BHVN	Biohaven Ltd
27/07/2023	07:42	Dow Jones News	Biohaven Told That FDA Won't Review NDA Application for Troriluzole	NYSE:BHVN	Biohaven Ltd
27/07/2023	06:00	PR Newswire (US)	Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates	NYSE:BHVN	Biohaven Ltd